Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-16-Speech-3-224-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-02-16"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20110216.11.3-224-000"2
lpv:hasSubsequent	lp_eu:2011-02-16-Speech-3-225-0002
lpv:speaker	lp:Jean-Luc Mélenchon2
lpv:spokenAs	vice-chair; AFET (2009-07-16--2011-10-04)3 unknown; Front de gauche pour changer d’Europe (2009-07-14--2014-06-30)3 substitute; CULT (2009-07-16--2012-01-18)3 substitute; Delegation for relations with the Maghreb countries and the Arab Maghreb Union (2009-09-16--2014-06-30)3 member; Delegation for relations with the Mercosur countries (2009-09-16--2014-06-30)3 member; EUL/NGL (2009-07-14--2014-06-30)3 member; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3
lpv:translated text	"Parliament’s amendments do not call for the safety systems to be extended to over-the-counter medicines. Nevertheless, our fellow citizens purchase larger numbers of these medicines. Their health is therefore at risk. Nor do they call for the obligation for the European Medicines Agency to exercise total transparency with regard to its research and to the collusion between its officials and the pharmaceutical companies. This, however, is necessary. The scandalous case of benfluorex, known by the name of Mediator in France, is proof positive of this. However, the amendments tabled are along the right lines, particularly those concerning the public authentication of Internet sites and sanctions. I am therefore voting for this report."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph